ReviewThe Journal of clinical and aesthetic dermatology2026
The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a chronic, inflammatory condition that has a substantial effect on quality of life. Tyrosine kinase 2 (TYK2) inhibitors have emerged as a promising class of agents for treating psoriasis.
objectiveTo summarize the current evidence on TYK2 inhibitors and their role in the management of psoriasis.
methodsA comprehensive literature search was conducted using a combination of the keywords "psoriasis," "tyrosine kinase," "pathogenesis," "mechanism of action," and "emerging therapies." The authors reviewed all studies and included those that addressed the topic of the review.
resultsTYK2 plays an integral role in the pathogenesis of psoriasis. Targeting TYK2 as a therapeutic pathway has led to significant improvement in disease severity and quality of life. Deucravacitinib was the first TYK2 inhibitor approved by the Unitefor moderate-to-severe plaque psoriasis. Zasocitinib and envudeucitinib are 2 agents currently undergoing late-stage clinical trials for psoriasis. The mechanism of action for these therapies is similar, targeting the JH2 pseudokinase domain of TYK2, but each has distinct features that differentiate their effectiveness and safety. Several other TYK2 inhibitors are in earlier development, including D-2570, ICP-488, AC-201, and TLL-018. LIMITATIONS: This review is limited by the information available in the published literature. In addition, comparisons between studies are limited as varying methodologies were used.
conclusionTYK2 inhibition represents a significant advancement for the treatment of psoriasis. Continued research will enable optimization of these agents in managing psoriasis and related immune-mediated diseases.
Indexed as
Identifiers
42761984PMC13588483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.